J. Goldman & Co’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

J. Goldman & Co’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-202,500	Closed	-$1.22M	–	539
2022 Q4	$1.22M	Buy	+202,500	New	+$1.11M	0.06%	211
2022 Q3	–	Sell	-67,500	Closed	-$403K	–	541
2022 Q2	$403K	Sell	67,500 -67,500	-50%	-$346K	0.02%	291
2022 Q1	$630K	Buy	+135,000	New	+$403K	0.03%	279

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

J. Goldman & Co's CTIC Position: Q2 2023 in Review

J. Goldman & Co sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 970,584 shares — an estimated $4.08M sold.

J. Goldman & Co first reported a position in CTIC in Q1 2022 and held it in 5 quarters. The position peaked at $4.08M in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

J. Goldman & Co reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
J. Goldman & Co sold 970,584 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $4.08M.
J. Goldman & Co first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2022 and held it in 5 quarters.
J. Goldman & Co's CTI BioPharma Corp. (DE) Common Stock position peaked at $4.08M in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on J. Goldman & Co's 13F filing for Q2 2023, filed 14 Aug 2023.